MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of n ... ovel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. Pracinostat is in clinical development by Helsinn Group, MEI’s global licensee, for high and very high-risk myelodysplastic syndrome or MDS. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details. read more